A 62-year-old woman presents with a 3-year history of progressive pain and stiffness in both knees, worse in the morning and after activity. Physical examination reveals bony enlargement of the knees, crepitus on movement, and mild varus deformity. Plain radiographs show joint space narrowing, osteophytes, and subchondral sclerosis bilaterally. She has tried paracetamol 500 mg thrice daily for 2 weeks with minimal relief. What is the most appropriate next step in management?

Explanation

## Management Approach to Symptomatic Osteoarthritis **Key Point:** The stepwise management of osteoarthritis follows a pyramid: non-pharmacological → pharmacological (simple analgesics optimized → NSAIDs) → intra-articular injections → surgical intervention. Before escalating to oral NSAIDs, guidelines recommend optimizing the current analgesic regimen first. ### Why Increasing Paracetamol to Maximum Dose + Topical NSAIDs is Correct This patient has been on **subtherapeutic paracetamol** (500 mg TDS = 1.5 g/day) — well below the recommended maximum of 4 g/day (or 3 g/day in elderly). Per EULAR, OARSI, and NICE guidelines, the appropriate next step after inadequate response to a low-dose simple analgesic is to **optimize that analgesic to its maximum tolerated dose** before escalating to oral NSAIDs. Topical NSAIDs (e.g., diclofenac gel) are also recommended as an adjunct at this stage, particularly in older patients, as they provide localized relief with minimal systemic side effects. **High-Yield:** NICE CG177 (Osteoarthritis) and OARSI guidelines recommend paracetamol at full dose (up to 4 g/day) as the first-line oral analgesic for OA. Topical NSAIDs are preferred over oral NSAIDs in patients ≥60 years due to lower GI and cardiovascular risk. **Clinical Pearl:** Oral NSAIDs are the next step only after failure of optimized paracetamol ± topical NSAIDs. In a 62-year-old woman, the GI and cardiovascular risks of oral NSAIDs (especially indomethacin, which has the highest GI toxicity among NSAIDs) must be carefully weighed. ### Management Pyramid for Osteoarthritis ```mermaid flowchart TD A[Symptomatic OA]:::outcome --> B{Adequate trial of simple analgesics at MAX dose?}:::decision B -->|No| C[Optimize Paracetamol to 4g/day + Topical NSAIDs + Physiotherapy]:::action B -->|Yes| D{Pain controlled?}:::decision D -->|Yes| E[Continue + Exercise/Weight management]:::action D -->|No| F[Add oral NSAIDs + PPI + Physiotherapy]:::action F --> G{Adequate response?}:::decision G -->|Yes| H[Maintain therapy]:::action G -->|No| I[Intra-articular injections or Arthroplasty]:::action ``` ### Comparison of Analgesic Options | Agent | Efficacy in OA | GI Risk | CV Risk | Use in This Case | |-------|---|---|---|---| | Paracetamol (optimized) | Modest–moderate | Minimal | None | **First — optimize dose** | | Topical NSAIDs | Mild–moderate (localized) | Minimal | None | **Add at this stage** | | Oral NSAIDs | High | Moderate–high (age 62) | Moderate | Next step if above fails | | COX-2 inhibitors | High | Minimal GI | Moderate CV | Alternative if GI intolerance | ### Why Option C (Oral NSAIDs) is Premature Jumping to oral NSAIDs before optimizing paracetamol violates the stepwise approach recommended by EULAR and OARSI. Indomethacin in particular carries the **highest GI toxicity** among NSAIDs and is generally avoided as a first-choice NSAID in elderly patients (Beers Criteria). Oral NSAIDs are appropriate only after failure of optimized conservative therapy. ### Why Surgery is Not Yet Indicated Arthroscopic debridement has **no proven benefit** in OA (AAOS guidelines, Level I evidence). Total knee arthroplasty is reserved for severe, refractory OA with significant functional impairment after failure of all conservative measures. **Reference:** NICE Clinical Guideline CG177 (Osteoarthritis: care and management); OARSI Guidelines for Hip and Knee OA (Bannuru et al., 2019); KD Tripathi Essentials of Medical Pharmacology, 8th ed.